2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5513 Efficacy and safety of frontline asciminib in newly diagnosed chronic myeloid leukemia: Interim analysis of a phase II trial

Maria Rita Khouri, MD, Elias Jabbour, MD2, Fadi G. Haddad, MD3, Ghayas C. Issa, MD4, Jayastu Senapati, MBBS, MD, DM5, Hannah Goulart, MD6, Alex Bataller, MD, PhD7, Tapan Kadia I, MD8, Jennifer Veazie9, Maria Villatoro10, Joseph Castellano, MD11, Guillermo Montalban-Bravo, MD12, Naveen Pemmaraju, MD13, Sara Dellasala, BSc14, Hagop Kantarjian, MD15
1 MD Anderson Cancer Center, Houston, Texas, United States
2 MD Anderson Cancer Center, Houston, Texas, United States
3 MD Anderson Cancer Center, Houston, Texas, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 MD Anderson Cancer Center, Houston, Texas, United States
6 MD Anderson Cancer Center, Houston, Texas, United States
7 MD Anderson Cancer Center, Houston, Texas, United States
8 MD Anderson Cancer Center, Houston, Texas, United States
9 MD Anderson Cancer Center, Houston, Texas, United States
10 MD Anderson Cancer Center, Houston, Texas, United States
11 MD Anderson Cancer Center, Houston, Texas, United States
12 MD Anderson Cancer Center, Houston, Texas, United States
13 MD Anderson Cancer Center, Houston, Texas, United States
14 MD Anderson Cancer Center, Houston, Texas, United States
15 MD Anderson Cancer Center, Houston, Texas, United States

Background
Asciminib, a first-in-class inhibitor that specifically targets the ABL myristoyl pocket, has demonstrated favorable efficacy and tolerability in chronic myeloid leukemia (CML). We report an interim analysis of an investigator-initiated phase II trial evaluating asciminib as frontline therapy for newly diagnosed CML.

Methods
Patients with newly diagnosed CML in chronic phase, or accelerated phase defined solely by clonal evolution, received asciminib 80 mg once daily. The primary endpoint was the proportion of patients achieving major molecular response (MMR; BCR::ABL1 ≤0.1% on the International Scale [IS]) by 12 months. Molecular response categories at each landmark reflected the deepest response achieved. Adverse events (AEs) were graded according to CTCAE version 5.0. Overall survival (OS) and event-free survival (EFS) were estimated using the Kaplan–Meier method. Data were analyzed as of July 28, 2026.

Results
Eighty patients were treated. The median age at diagnosis was 48 years (range, 21–79), and 47 patients (59%) were male. Sokal risk was low in 38 patients (47%), intermediate in 31 (39%), and high in 11 (14%). With a median follow-up of 14 months (range, 3–43), the cumulative best overall response was major cytogenetic response (MCyR or BCR::ABL1 ≤10% IS) in 74 patients (93%), complete cytogenetic response (CCyR or BCR::ABL1 ≤1% IS) in 70 (88%), MMR in 51 (64%), MR4 in 34 (43%), and MR4.5 in 22 (28%).

By 3 months, among 79 evaluable patients, MCyR was achieved in 69 patients (87%), CCyR in 56 (71%), MMR in 21 (27%), MR4 in 8 (10%), and MR4.5 in 4 (5%). By 6 months, among 69 evaluable patients, CCyR was achieved in 59 (86%), MMR in 43 (62%), MR4 in 23 (33%), and MR4.5 in 18 (26%). By 12 months, among 53 evaluable patients, CCyR was achieved in 49 (92%), MMR in 41 (77%), MR4 in 26 (49%), and MR4.5 in 17 (32%).

ASXL1 mutations were detected in 5 of 55 patients (9%) evaluated by next-generation sequencing. Two achieved MR4.5, two achieved CCyR (one later lost response with emergence of A337T and F497L mutations), and one has not achieved MCyR by 6 months.

The most common AEs considered possibly or probably related to asciminib were elevated lipase (Grade[G] 1-2, 19%; G3+, 5%), thrombocytopenia (G1-2, 2.5%; G3-4, 20%), fatigue (G1-2, 20%), and abdominal pain (G1-2, 15%; G3+, 1%). Four patients developed pancreatitis (G2, 2.5%; G3, 2.5%). One 71-year-old patient with hypertension developed a fatal acute coronary syndrome after 2.5 months of therapy.

Asciminib was discontinued in 12 patients (15%): 5 due to adverse events (pancreatitis, n=3; cytopenias and stroke, n=1 each), 6 due to disease progression, and 1 due to withdrawal of consent related to social constraints while in MR4. Among patients with disease progression, 2 lost CCyR with emergence of A337T/F497L and P465A/D381E mutations, respectively, while the remaining 4 never achieved CCyR and had rising BCR::ABL1 transcript levels prompting change in therapy. The estimated 12-month OS and EFS rates were 99% and 86%, respectively.

Conclusions
Frontline asciminib demonstrated substantial activity in newly diagnosed CML, with 12-month MMR rate of 77%. The safety profile was generally consistent with previous reports, although continued follow-up is warranted. Emergent myristoyl-pocket mutations were identified in patients with acquired resistance.

 

Maria Rita Khouri, MD: No relevant conflicts of interest to declare.